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Purpose: This analysis examined potential causes of the lack of vaccine effectiveness (VE) of live attenu-
ated influenza vaccine (LAIV) against A/H1N1pdm09 viruses in the United States (US) during the 2013–
2014 season. Laboratory studies have demonstrated reduced thermal stability of A/California/07/2009,
the A/H1N1pdm09 strain utilized in LAIV from 2009 through 2013–2014.
Methods: Post hoc analyses of a 2013–2014 test-negative case-control (TNCC) effectiveness study inves-
tigated associations between vaccine shipping conditions and LAIV lot effectiveness. Investigational sites
provided the LAIV lot numbers administered to each LAIV recipient enrolled in the study, and the vaccine
distributor used by the site for commercially purchased vaccine. Additionally, a review was conducted of
2009–2014 pediatric observational TNCC effectiveness studies of LAIV, summarizing effectiveness by
type/subtype, season, and geographic location.
Results: From the 2013 to 2014 TNCC study, the proportion of LAIV recipients who tested positive for
H1N1pdm09 was significantly higher among children who received a lot released between August 1
and September 15, 2013, compared with a lot shipped either earlier or later (21% versus 4%; P < 0.01).
A linear relationship was observed between the proportion of subjects testing positive for H1N1pdm09
and outdoor temperatures during truck unloading at distributors’ central locations. The review of LAIV
VE studies showed that in the 2010–2011 and 2013–2014 influenza seasons, no significant effectiveness
of LAIV against H1N1pdm09 was demonstrated for the trivalent or quadrivalent formulations of LAIV in
the US, respectively, in contrast to significant effectiveness against A/H3N2 and B strains during 2010–
2014.
Conclusions: This study showed that the lack of VE observed with LAIV in the US against H1N1pdm09
viruses was associated with exposure of some LAIV lots to temperatures above recommended storage
conditions during US distribution, and is likely explained by the increased susceptibility of the A/
California/7/2009 (H1N1pdm09) LAIV strain to thermal degradation.
Conclusions: Clinical trial registry: NCT01997450
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Influenza vaccine strain recommendations are updated annu-
ally by the World Health Organization and national public health
bodies to optimize vaccine effectiveness (VE) in the context of anti-
genic changes in circulating influenza strains. To monitor the
annual effectiveness of influenza vaccines, national public health
agencies in the United States (US), Canada, Australia, and Western
Europe have supported annual observational studies of VE [1–5]
using a prospective, test-negative case control (TNCC) design [6].
In 2013–2014, MedImmune (Gaithersburg, MD), manufacturer of
live attenuated influenza vaccine (LAIV, FluMist QuadrivalentTM),
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children 2–17 years of age during 4 consecutive influenza seasons
to fulfill a regulatory requirement. These TNCC studies are more
feasible from operational and ethical standpoints than randomized,
placebo-controlled prospective trials. As observational studies,
TNCC studies are vulnerable to bias, and small sample sizes can
lead to imprecise effectiveness estimates. However, TNCC studies
have been shown to provide robust estimates of annual VE and
have detected clinically meaningful deficits in vaccine perfor-
mance [7,8].
In 2013–2014, the TNCC studies conducted by the US Centers
for Disease Control and Prevention (CDC) and MedImmune demon-
strated no significant VE of LAIV in children during a season dom-
inated by A/H1N1pdm09 strains [9,10]. There was no meaningful
circulation of A/H3N2 strains during this season, and in the Med-
Immune TNCC study, high and statistically significant effectiveness
was observed against circulating B strains. The observation of low
VE against A/H1N1pdm09 strains was unexpected in light of
results of previous randomized controlled trials in children that
had demonstrated consistently high efficacy of LAIV against anti-
genically similar seasonal influenza strains, including seasonal A/
H1N1 strains [11], and published results of TNCC studies con-
ducted in 2009–2013 [12–17].
As a live virus vaccine, LAIV is susceptible to heat degradation
[18] and it is recommended to be stored and transported at 36–
46 F (2–8 C) [19]. Additionally, laboratory experiments have
demonstrated that the A/California/2009/07 strain had an
increased susceptibility to degradation at high temperatures (well
above those recommended for storage and handling) due to
reduced hemagglutinin stability [20]. As a result, potential expo-
sure to temperatures over the recommended 36–46 F (2–8 C)
during vaccine shipping and handling became one focus of investi-
gation to explain low VE against A/H1N1pdm09 strains. The cur-
rent study describes results of post hoc analyses of the
MedImmune TNCC study that investigated an association between
the lack of LAIV effectiveness against H1N1pdm09 strains and vac-
cine lot handling conditions during distribution. A comprehensive
review of the available data from TNCC and randomized studies
describing LAIV VE in children from 2009 to 2010 through 2013–
2014 was also conducted to provide additional context regarding
potential causes of the lack of LAIV effectiveness against H1N1p-
md09 strains in the US in 2013–2014.2. Materials and methods
The design, methods, and results of the MedImmune TNCC
study conducted during the 2013–2014 influenza season have
been described previously [9]. For the current analysis, investiga-
tional sites provided the lot numbers of LAIV administered to each
LAIV recipient enrolled in the study, as well as the vaccine distrib-
utors used by the site in the 2013–2014 season.
Most LAIV was shipped at 20 C by refrigerated trucks from
the MedImmune facility in Louisville, Kentucky, to third-party dis-
tributors’ central locations across the US in Kentucky, Colorado,
California, and Tennessee. LAIV doses not shipped by truck, which
represented 14% (23/169) of doses included in this analysis, were
shipped in insulated parcels that contained dry ice to maintain fro-
zen temperatures during shipping and handling. Examination of US
distributor standard operating procedures associated with receipt
of truck shipments identified that opportunities existed for expo-
sure of the vaccine to temperatures above the 36–46 F (2–8 C)
recommended storage temperature at 3 time-points: during
unloading of truck vaccine shipments from MedImmune, for up
to 2 h following unloading, and for up to 2 h during packing of LAIV
for shipment to healthcare professionals. No data by vaccine lotwere available to describe temperature exposures during vaccine
shipment packing, which occurs within the distribution facility
under controlled conditions. However, as truck unloading was con-
firmed to occur in a setting that was open to outdoor air, the poten-
tial temperature exposure at unloading could be estimated based
on the outdoor air temperature at the distributor location.
The specific date and time of truck unloading was available from
bills of lading and FedEx Custom Critical truck monitoring reports
for each LAIV lot shipped. The outdoor temperature at the distrib-
utors’ locations at the nearest hour of LAIV unloading was available
from National Oceanic and Atmospheric Administration reports
[21].
Consequently, two indicators of LAIV lot shipping conditions
could be analyzed in the present study. The first was the calendar
date when a vaccine lot was shipped from the MedImmune storage
facility to the distributor’s central site. The second was the outdoor
temperature at the time of truck unloading of the specific vaccine
lot. The proportion of LAIV recipients testing positive for
H1N1pdm09 strains and LAIV effectiveness were therefore evalu-
ated as a function of these two indicators. Data from unvaccinated
children enrolled during the period of H1N1pdm09 strain circula-
tion and LAIV recipients with documented shipping conditions
were included in the analysis. LAIV recipients who tested positive
for another influenza virus were excluded from the control group
in the effectiveness analyses. The proportions of LAIV recipients
testing positive for H1N1pdm09 strains were adjusted by logistic
regression for each of the following potential confounders in turn:
visit date (by month), site, age group (2–4 years, 5–8 years, 9–
17 years), vaccination date (before October, during October, after
October 2013), and health insurance status (privately insured
yes/no). VE (%) was defined as 100  (1  adjusted odds ratio), in
which the odds ratio represents the odds of exposure to LAIV
among influenza cases versus test-negative controls. Adjustment
for date of enrollment, site, health insurance status and prior vac-
cination was conducted with a multivariate logistic regression
model. All statistical analyses were conducted with SAS version
9.3 (SAS Institute, Cary, NC).
To provide additional context and to assist with efforts to iden-
tify potential causes for the lack of LAIV effectiveness against
H1N1pmd09 strains in the US in 2013–2014, LAIV pediatric effec-
tiveness studies using an observational TNCC design and con-
ducted by the CDC Flu VE Network in the US and the Sentinel
Provider Surveillance Network in Canada were reviewed for the
time period from the emergence of the H1N1pdm09 strain (i.e.,
2009–2010) through 2013–2014. Effectiveness results from these
studies were summarized by type/subtype, season, and geographic
location.3. Results
The hourly outdoor temperatures at each distributor’s location
from July 15 to September 30, 2013 are presented in Fig. 1, with
indications for the times when each lot was received and unloaded.
As shown in Table 1, the proportion of LAIV recipients who tested
positive for H1N1pdm09 was significantly higher among children
who received a lot shipped between August 1 and September 15,
2013 compared with children who were administered LAIV from
a lot shipped either earlier or later (21% [21/98] and 4% [3/71],
respectively; P < 0.01). This difference remained significant after
adjusting for visit date, site, age group, vaccination date, and
health insurance status. Doses shipped between August 1 and
September 15, 2013 accounted for 58% (98/169) of LAIV recipients
but 87.5% (21/24) of the A/H1N1pdm09 cases detected among LAIV
recipients. VE against H1N1pdm09 strains (Table 2) was 32%
(95% CI: 149 to 30) for LAIV lots shipped between August 1 and
AB
C
Fig. 1. Hourly outdoor temperature and temperatures during offloading at distributors located in: (A) California, (B) Tennessee, (C) Colorado, and (D) Kentucky.
5068 H. Caspard et al. / Vaccine 34 (2016) 5066–5072September 15, 2013 compared with 81% (95% CI: 31 to 95) for LAIV
lots shipped either earlier or later; the difference between these
two estimates was statistically significant (P < 0.05).The proportions of A/H1N1pdm09 cases among LAIV recipients
as a function of the outdoor temperature at the central distributor
site at unloading are shown in Fig. 2. A linear relationship was
DFig. 1 (continued)
Table 1
Proportion of A/H1N1pdm09 cases among LAIV recipients as a function of lot release
date.
LAIV recipients enrolled in the study by lot Shipping date A/H1N1pdm09
influenza cases
Release before 01 Aug 2013
BH2029 (n = 32) 26 Jul 2013 3
BH2173 (n = 12) 30 Jul 2013 0
Total (n = 44) 7% (3/44)
Release between 01 Aug 2013 and 15 Sep 2013
BH2090 (n = 1) 05 Aug 2013 0
BH2091 (n = 3) 06 Aug 2013 1
BH2124 (n = 15) 06 Aug 2013 2
BH2187 (n = 1) 19 Aug 2013 0
BJ2109 (n = 5) 20 Aug 2013 1
BH2186 (n = 23) 27 Aug 2013 5
BJ2013 (n = 11) 27 Aug 2013 4
BJ2154 (n = 34) 04 Sep 2013 6
BJ2014 (n = 5) 04 Sep 2013 2
Total (n = 98) 21% (21/98)
Release after 15 Sep 2013
BK2019 (n = 16) 16 Sep 2013 0
BK2023 (n = 5) 23 Sep 2013 0
BK2065 (n = 1) 01 Nov 2013 0
BL2049 (n = 2) 08 Nov 2013 0
BL2148 (n = 2) 20 Nov 2013 0
BN2195 (n = 1) 09 Jan 2014 0
Total (n = 27) 0% (0/27)
Table 2
LAIV effectiveness estimates against A/H1N1pdm09 as a function of shipping conditions in 2013–2014.
Unvaccinated subjects n = 312 LAIV recipients (n = 165a)
Lots shipped in August
and early September, 2013
Lots exposed to
temperature P84 F (29 C)
Yes No Yes No
Cases 68 21 3 17 7
Controls 244 75 66 63 78
Crude effectiveness 1 (75 to 42)c 84 (46 to 95)c 3 (76 to 47)c 68 (27 to 86)c
Adjusted effectivenessb 32 (149 to 30)c 81 (31 to 95)c 30 (158 to 35)c 60 (1 to 84)c
a Four LAIV recipients who tested positive for another influenza strain were excluded from this analysis.
b Adjustment on date of enrollment, site, health insurance status, and prior vaccination.
c 95% confidence interval.
Fig. 2. Association between outdoor temperature at truck unloading and H1N1
illness by lot in LAIV recipients. Circles represent individual lots; circle size is
proportional to number of subjects receiving the lot. Lots used in 66 subjects were
combined with lots experiencing most similar unloading temperatures. Lots
shipped by refrigerated parcel (not by truck) were classified as being exposed to
55 F (13 C). LAIV = live attenuated influenza vaccine.
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for H1N1pdm09 with increasing temperatures at truck unloading
of the vaccine (Pearson’s correlation coefficient = 0.195; P = 0.01).
The study population was balanced between LAIV recipients who
received vaccine from lots that were potentially exposed to out-
door temperatureP84 F (29 C) or not: n = 82 and n = 87, respec-
tively. The proportion of LAIV recipients who tested positive for A/
H1N1pdm09 was significantly higher when the ambient tempera-
ture was P84 F (21% [17/82] versus 8% [7/87]; P = 0.02). This dif-
ference remained significant after adjusting for site, age group,
vaccination date, and health insurance status. VE against the
H1N1pdm09 strain (Table 2) was 60% (95% CI: 1 to 84) for unex-
posed LAIV lots compared with 30% (95% CI: 158 to 35) for LAIV
lots unloaded in outdoor temperature P84 F (29 C); the differ-
ence between these two estimates was statistically significant
(P < 0.05).
Fig. 3 depicts VE estimates against circulating A/H3N2, B and A/
H1N1pdm09 strains from TNCC studies conducted in the US and
Canada from 2009 to 2010 through 2013–2014 in children
69 years of age, as results were consistently available across stud-
ies in this age subgroup [9,22,23]. LAIV was consistently effective
against H3N2 and B strains in all study seasons. When adminis-
tered as a monovalent formulation in the US during the 2009–
2010 season, LAIV was effective against H1N1pdm09 strains when
cases were assessed beginning 7 days after vaccination, with a VE
of 82% (95% CI: 14 to 96) [14]. In the 2010–2011 and 2013–2014
influenza seasons, no significant effectiveness of LAIV against
H1N1pdm09 in the US was demonstrated for the trivalent or
quadrivalent formulations of the vaccine, respectively, in contrast
to the high effectiveness demonstrated against A/H3N2 and B
strains during those same seasons [9,10,22,24,25]. However, LAIV
was effective against H1N1pdm09 when administered as a triva-2009–10 CDC ≥14 DaysIIV
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Fig. 3. Vaccine effectiveness against H1N1pdm09, H3N2, and B strains in children since
of identified strains in the 2012–2013 CDC study in children aged 8 years or less were
influenza vaccine; LAIV = live attenuated influenza vaccine; SPSN = Sentinel Provider Sulent formulation in the 2013–2014 season in Canada, with a VE
of 85% (95% CI: 22 to 98) in children 2–8 years of age and 87%
(95% CI: 2 to 98) in children and adolescents 2–19 years of age in
British Columbia, Alberta, and Quebec [23]. Further evidence that
LAIV was effective in Canada during the 2013–2104 season was
provided by a cluster-randomized trial among elementary school
children in Ontario, during which 95% of influenza cases were
due to A/H1N1pdm09 strains [26]. The incidence of influenza
among children vaccinated with LAIV was 0.13 per 1000 person-
days compared with 1.24 per 1000 person-days for children vacci-
nated with inactivated influenza vaccine (IIV); (P < 0.05). Overall,
the review of available LAIV VE estimates from 2009 to 2010
through 2013–2014 demonstrated that the lack of LAIV effective-
ness was limited to A/H1N1pdm09 strains and to US studies con-
ducted in 2010–2011 and 2013–2014.4. Discussion
These analyses suggest that the known increased susceptibility
of the A/California/7/2009pdm09 LAIV strain to thermal degrada-
tion and potential exposure of some LAIV lots to heat during US
distribution may explain the lack of VE observed with LAIV in
2013–2014 in the US. LAIV effectiveness against A/H1N1pdm09
strains was significantly associated with both vaccine shipping
date and the outdoor temperatures to which lots could have been
exposed during US distribution. LAIV lots demonstrated reduced
effectiveness when shipped between August 1 and September 15
or when unloaded at distributors at a time when outdoor
temperatures were P84 F (29 C). However, LAIV was signifi-
cantly effective when the lots were shipped before August or after
mid-September 2013, and LAIV effectiveness was very close toAdjusted VE, %
Effectiveness against
A/H3N2 strains
Effectiveness against
B strains
50
64
20 40 60 80 100 0 20 40 60 80 100
64 62
76 75
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75
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Adjusted VE, %
2009 through 2013–2014. The grayed background rows represent IIV. ⁄The majority
B strains, but there was also a large proportion of A/H3N2 strains. IIV = inactivated
rveillance Network (data collected in Alberta, British Columbia and Quebec).
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outdoor temperatures were <84 F.
A review of data since the 2009 influenza A/H1N1pdm09 pan-
demic indicated that LAIV was similarly not effective against A/
H1N1pdm09 strains in the 2010–2011 season in the US, when
most LAIV doses were shipped before mid-September. In contrast,
significant effectiveness was observed in the US in 2009–2010
when LAIV was shipped exclusively after mid-September, and in
2013–2014 in Canada when LAIV was shipped starting in Novem-
ber and where outdoor temperatures are typically lower than in
the US. The conclusion that some LAIV lots were effective in the
US in 2013–2014 is also supported by the trend of effectiveness
observed in a US household-based cohort study [27].
The association between reduced effectiveness against
H1N1pdm09 in the US and potential heat exposure during LAIV
distribution is supported by laboratory studies that documented
reduced thermal stability of A/California/7/2009pdm09. Specifi-
cally, a glutamic acid (E) residue at position 47 (E47) of the hemag-
glutinin stalk that was present in early H1N1pdm09 wild-type
strains, including the A/California/7/2009 strain, destabilizes the
hemagglutinin trimer, rendering it more vulnerable to inactivation
upon exposure to extreme heat or acid and reducing its infectivity
in ferrets [20]. Additionally, the hemagglutinin stalk E47 sequence
may have reduced the viral fitness of early H1N1pdm09 strains as
contemporary H1N1pdm09 strains have evolved to contain a
lysine at position 47, which increases hemagglutinin stability
[20]. When these laboratory studies were first conducted, they
did not appear to have any clinical significance, given the demon-
stration of high effectiveness of the A/California/7/2009 LAIV strain
in US children in the 2009–2010 season. However, the observed
reduced thermal stability is consistent with the hypothesis that
the A/California/7/2009 LAIV strain may have been compromised
by heat exposure during US distribution in 2010–2011 and
2013–2014 when LAIV was distributed during warmer months,
resulting in reduced vaccine potency at the time of administration
and thus reduced effectiveness. A previous study demonstrated
substantially reduced efficacy of LAIV when administered at a
potency of 106 viral particles compared with the standard LAIV
potency of 107 [28]. Multiple clinical studies in children have
demonstrated vaccine virus replication and immunologic
responses with the A/California/07/2009 LAIV strain [29–32], pro-
viding evidence that the A/California/7/2009 LAIV strain was bio-
logically active in humans, capable of replication, and able to
induce relevant strain-specific immunity when administered at full
potency.
These observed associations do not prove a causal link. It is pos-
sible that there is an alternative causal factor or factors that corre-
late with these findings. Additionally, the precise extent to which
vaccine lots may have exceeded their recommended storage tem-
peratures of 36–46 F (2–8 C) is unknown because there was no
direct monitoring of vaccine lot temperatures after receipt by dis-
tributors. However, following an extensive investigation into other
potential causes of the observed low LAIV VE in 2013–2014, no
other potential explanations have been identified that are consis-
tent with the available data regarding LAIV VE in recent seasons.
A comprehensive investigation of LAIV manufacturing and release
testing was conducted. Additionally, various potential explana-
tions for decreased vaccine effectiveness previously described in
randomized controlled trials or case-control observational studies
were evaluated. Specifically, low effectiveness of IIV has been pre-
viously associated with prior vaccination, poor antigenic match
between vaccine and circulating strains, ageP65 years, or waning
protection during the influenza season [7,16,33–39]. However, no
findings related to manufacturing, testing, prior vaccination, vac-
cine strain mismatch, or waning protection were identified that
might explain the lack of effectiveness of LAIV during the 2013–2014 season (data not shown). The hypothesis that viral interfer-
ence between the four LAIV vaccine strains could explain the
absence of effectiveness against H1N1pdm09 strains is also not
consistent with the available clinical evidence [10,14,22,23]. In
particular, with the observations of significant variability by vac-
cine lot or the observation that the trivalent formulation was effec-
tive against A/H1N1pdm09 strains in Canada in 2013–2014 but not
in the US in 2010–2011.
Previous analyses of the TNCC studies conducted by the CDC
and MedImmune during the 2013–2014 season investigated
whether age or prior vaccination might be associated with the
low effectiveness against A/H1N1pdm09 strains [9,10,22]. In both
studies, VE trended higher in older children compared with
younger children. Additionally, data on LAIV VE available from
other TNCC and randomized studies demonstrated that 2009–
2014 trivalent and quadrivalent LAIV formulations were consis-
tently effective in children against circulating H3N2 and B strains
[14,37,40]. These observations are not consistent with the hypoth-
esis that preexisting immunity due to more natural influenza infec-
tions or more years of annual vaccination with increasing age of US
children were responsible for the lack of LAIV VE. On the contrary,
the trend toward higher VE in older children observed in the CDC
and MedImmune studies in 2013–2014 would be consistent with
the ability of a reduced-potency LAIV to boost existing immunity
in children previously infected with wild-type H1N1pdm09
influenza.
In summary, this investigation showed that the lack of VE
observed with LAIV in the US against H1N1pdm09 viruses was
associated with exposure of some LAIV lots to temperatures above
the recommended storage conditions of 36–46 F (2–8 C) during
US distribution, and is likely explained by the increased suscepti-
bility of the A/California/7/2009 (H1N1pdm09) LAIV strain to ther-
mal degradation. Other recent LAIV strains without this
susceptibility to thermal degradation appear to have been unaf-
fected by heat exposures during US distribution in recent seasons.
Nevertheless, our findings reinforce the need for adherence to rec-
ommended storage temperatures throughout the entire vaccine
distribution chain. To ensure effectiveness against H1N1pdm09
strains in future seasons, the A/California H1N1pdm09 LAIV strain
has been replaced in the 2015–2016 LAIV formulation with an
antigenically equivalent A/H1N1pdm09 vaccine strain (A/Boli-
via/559/2013) that does not possess the E47 residue in the hemag-
glutinin stalk and is more stable.Conflicts of interest
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